Table 2.
Clinical Outcomes
| Outcome (N=54) | % | |
|---|---|---|
| Median number of cycles | 6 (1–31) | |
| Clinical benefit* | ||
| No | 27 | 50 |
| Yes | 27 | 50 |
| Best response | ||
| Partial response | 15 | 28 |
| Stable disease | 12 | 22 |
| Progressive disease | 27 | 50 |
| Reason off study (n = 53) | ||
| Progressive disease | 48 | 90 |
| Withdrew consent | 3 | 6 |
| Non- compliance | 1 | 2 |
| Toxicity | 1 | 2 |
| Current status | ||
| Alive with disease | 21 | |
| Deceased | 33 | |
| Median follow up | 17.9 (2 – 47) | |
| Median progression free survival | 5.7 months | |
| Median overall survival | 19.6 months | |
*
Confirmed after 4 cycles of therapy (16 weeks)